Report copyright - OSE:BGBIO Result First Quarter 2018 - BerGenBio · previously treated TNBC patients and 18% in NSCLC. PD-L1 negative patients remain particularly challenging. The BGBC007 and 008
Please pass captcha verification before submit form
Please pass captcha verification before submit form